Mesutoclax vs Venetoclax

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: BCL-2 · full Acute Myeloid Leukemia pipeline

Mesutoclax

Developed by Beijing InnoCare Pharma Tech Co.

Phase 3 in Acute Myeloid Leukemiasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT06656494 (registry estimate)

No aligned efficacy figure on record for this race.

Venetoclax

Marketed by AbbVie and partners

Approved in Acute Myeloid Leukemiasmall molecule
Reliable signal

NCT02993523 · Phase 3 · active, not recruiting

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial whose primary endpoint, overall survival, was met with a statistically significant improvement for venetoclax plus azacitidine. A power calculation was reported in the protocol and statistical analysis plan, and 431 participants were randomized against a planned 400.

Next expected readout: November 2026 · NCT03850574 (registry estimate)

Reported efficacy

Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) (missed)

Result source: NCT03069352

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMesutoclaxVenetoclax
OS, median—Trial running · NCT07925190—Not posted · NCT05654194
Complete remission—Trial running · NCT0792519013.3%b400 mg + 75 mg · n 30NCT03941964
1 other result
  • 26.7% 400 mg + 20 mg · n 30 · Phase 3 · secondary NCT03941964
Event-free survival, median—Trial running · NCT079251907.7 vs 11.2vs Venetoclax + Azacitidine20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 · n 83NCT04266795
Duration of response, median—Trial running · NCT07925190—Not posted · NCT05654194

OS, median

Mesutoclax
—Trial running · NCT07925190
Venetoclax
—Not posted · NCT05654194

Complete remission

Mesutoclax
—Trial running · NCT07925190
Venetoclax
13.3%b400 mg + 75 mg · n 30NCT03941964
1 other result
  • 26.7% 400 mg + 20 mg · n 30 · Phase 3 · secondary NCT03941964

Event-free survival, median

Mesutoclax
—Trial running · NCT07925190
Venetoclax
7.7 vs 11.2vs Venetoclax + Azacitidine20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 · n 83NCT04266795

Duration of response, median

Mesutoclax
—Trial running · NCT07925190
Venetoclax
—Not posted · NCT05654194
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Mesutoclax: no structured comparison results are available for Acute Myeloid Leukemia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Mesutoclax: 0 of 4 rows · Venetoclax: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricVenetoclax
Dropout rate
n/a: no completion milestone400 mg + 20 mg/m^2a
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
show 8 more results
n/a: no completion milestone400 mg + 36 mg/m^2
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg + 50 mg/m^2
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg + 200 mg
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg + 300 mg
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
76.7%400 mg + 75 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
63.3%400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04277442 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
4.3%400 mg + 20 mg/m^2a
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
show 8 more results
0%400 mg + 36 mg/m^2
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 50 mg/m^2
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
3.3%400 mg + 200 mg
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 300 mg
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
3.3%400 mg + 75 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
26.7%400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
22.9%20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
—
NCT04277442 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
21.7%400 mg + 20 mg/m^2a
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
show 8 more results
30.4%400 mg + 36 mg/m^2
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
25%400 mg + 50 mg/m^2
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
16.7%400 mg + 200 mg
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
18.8%400 mg + 300 mg
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
63.3%400 mg + 75 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
73.3%400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
76.5%20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
100%
NCT04277442 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
400 mg + 20 mg/m^2a
neutropenia 56.5%
thrombocytopenia 34.8%
diarrhoea 26.1%
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
show 8 more results
400 mg + 36 mg/m^2
neutropenia 69.6%
thrombocytopenia 56.5%
anaemia 34.8%
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
400 mg + 50 mg/m^2
neutropenia 80%
thrombocytopenia 55%
anaemia 35%
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
400 mg + 200 mg
nausea 50%
diarrhoea 43.3%
neutropenia 33.3%
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
400 mg + 300 mg
nausea 56.3%
neutropenia 56.3%
vomiting 56.3%
NCT04102020 · Phase 3 · registry result, not featured evidence · combination
400 mg + 75 mg
anaemia 76.7%
neutrophil count decreased 63.3%
nausea 56.7%
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
400 mg + 20 mg
anaemia 80%
platelet count decreased 53.3%
white blood cell count decreased 53.3%
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
neutropenia 58%
thrombocytopenia 45.7%
constipation 42%
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
NCT04277442 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Venetoclax

CR + CRi 70% (n=30)400 mg + 75 mg
responder rate · % of participants
No placebo or comparator arm
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
63.3% (n=30)400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
Complete Remission 13.3% (n=30)400 mg + 75 mg
responder rate · % of participants
No placebo or comparator arm
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
26.7% (n=30)400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
Complete Remission With Incomplete Recovery 56.7% (n=30)400 mg + 75 mg
responder rate · % of participants
No placebo or comparator arm
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
36.7% (n=30)400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
RBC Transfusion Independence 50% (n=30)400 mg + 75 mg
responder rate · % of participants
No placebo or comparator arm
Red blood cells (RBC)
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
60% (n=30)400 mg + 20 mg
Red blood cells (RBC)
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
Platelet Transfusion Independence 73.3% (n=30)400 mg + 75 mg
responder rate · % of participants
No placebo or comparator arm
Platelets
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
73.3% (n=30)400 mg + 20 mg
Platelets
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
Transfusion Independence 50% (n=30)400 mg + 75 mg
responder rate · % of participants
No placebo or comparator arm
RBC and platelets
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
60% (n=30)400 mg + 20 mg
RBC and platelets
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
Event-Free Survival 7.72 vs 11.24 Venetoclax + Azacitidine months20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
time to event · months
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
Overall 0% (n=1) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT04277442 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 participants as posted
Overall Survival 0%
time to event · count
No placebo or comparator arm
NCT04277442 · Phase 1 · registry result, not featured evidence · combination

Chronic Lymphocytic Leukemia

Shared mechanism: BCL-2 · full Chronic Lymphocytic Leukemia pipeline

Mesutoclax

Developed by Beijing InnoCare Pharma Tech Co.

Phase 2/3 in Chronic Lymphocytic Leukemiasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2030 · NCT06378138 (registry estimate)

No aligned efficacy figure on record for this race.

Venetoclax

Marketed by AbbVie and partners

Approved in Chronic Lymphocytic Leukemiasmall molecule
Partial signal

NCT02005471 · Phase 3 · completed

This randomized, open-label Phase 3 trial compared venetoclax plus rituximab with bendamustine plus rituximab in 389 patients with relapsed or refractory chronic lymphocytic leukaemia. The primary endpoint was progression-free survival as assessed by the investigator. Median progression-free survival was 54.7 months with venetoclax plus rituximab and 17.0 months with bendamustine plus rituximab (hazard ratio 0.23, 95% CI 0.18 to 0.29; p<0.0001). Neither patients nor investigators were masked to treatment, and progression was judged by the treating investigators.

Next expected readout: November 2026 · NCT04895436 (registry estimate)

Reported efficacy

Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death (Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)); Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines (Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)): Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) (met)

Result source: NCT02005471

Results for Chronic Lymphocytic Leukemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Mesutoclax: no structured comparison results are available for Chronic Lymphocytic Leukemia.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Venetoclax
Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) NCT02005471 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mesutoclax's landscape · Venetoclax's landscape